CD274 and triple-negative breast carcinoma: Several trials are studying the potential of SG in combination with Pembrolizumab: the NCT04468061 trial focuses on PD-L1-negative metastatic triple-negative breast cancer, the NCT05382286 trial aims to compare SG plus Pembrolizumab with treatment of choice (TPC) plus Pembrolizumab in terms of progression-free survival (PFS) in patients with previously untreated PD-L1-positive locally advanced inoperable or metastatic triple-negative breast cancer, and the NCT04434040 trial investigates the potential of SG and atezolizumab combination in preventing TNBC recurrence.